Med BioGene Reports Pre-Clinical Results of its Diagnostic Lymphoma DNA Bioarray

Med BioGene Inc. has announced the results of its  pre-clinical studies involving its Diagnostic Lymphoma Bioarray.

The studies of fifty RNA samples derived from human lymphoma tissues suggest that MBI's Diagnostic Lymphoma Bioarray differentiated between genes in both the diseased and healthy control samples.

Moreover, the results revealed a dissimilarity between six lymphoma subtypes (Diffuse Large B-Cell, Mantle Cell, Follicular, Hodgkin, Marginal Zone and Small Lymphocytic) and the healthy control samples, indicating that the bioarray is able to detect differential expression profiles.

The samples used in the studies did not include the subtype T-Cell Lymphoma; however, prior studies suggest that the bioarray is able to distinguish this subtype from healthy control samples.

Sample replicates were also similar to one another, indicating a consistency in the bioarray.

"We are very pleased with these results and are enthusiastic about the prospects of our Diagnostic Lymphoma Bioarray as an effective tool for the accurate and rapid detection of lymphoma subtypes," noted Dr. T. Nathan Yoganathan, Chief Scientific Officer of MBI.

"We have been able to narrow our lymphoma biomarkers to approximately 100 genes, thus increasing the effectiveness of the product as a manageable diagnostic tool."

"Further studies, however, may result in the finding of additional biomarkers that will be included in our bioarray."

"These studies were performed on GE Healthcare's CodeLink System using custom bioarrays made exclusively for, and containing genetic content developed by, Med BioGene."

"We are also in the process of confirming our results on a second platform utilizing Applied BioSystem's 7500 Real-Time PCR System."

"In addition to the use of our bioarray as a diagnostic tool, there is an increasing consensus in the medical community that effective biomarkers are needed to unlock innovation in therapeutic development and treatment," stated Erinn Broshko, Chief Executive Officer of MBI.

"With a robust set of qualified lymphoma biomarkers, the safety of new therapeutics could be increased, products could get to patients in less time and treatment decisions could be more informed. Med BioGene is truly at the forefront of personalized medicine."